McMaster University

McMaster University

Kathryn E Webert

, MD, MSc, FRCPC

Associate Professor, Pathology and Molecular Medicine

Division: Clinical Pathology
Associate Member: Medicine

Medical Director of Utilization Management
Medical, Scientific and Research Affairs Division
Canadian Blood Services
35 Stone Church Road, Suite 200
Ancaster, Ontario L9K 1S5
Telephone:  905-304-7282
Fax:  905-648-8417

kathryn.webert@blood.ca

Kathryn E Webert

Faculty Biography

Education and Professional Standing

BSc, Queen's University, 1992

MD, University of Western Ontario, 1996

FRCPC Internal Medicine, 2000

FRCPC Hematology 2001

MSc (HRM), McMaster University, 2009

FRCPC Clinical Investigator, 2009

Graduate Diploma in Health Services and Policy Research, Ontario Training Council and McMaster University, 2009


Interests

Research Focus

Dr. Webert's areas of research interest include bleeding in patients with bone marrow failure and the utilization of blood products. She was the co-principal investigator of a pilot clinical trial to investigate the role of hemoglobin level on the frequency of bleeding in patients with acute leukemia and patients undergoing stem cell transplantation. She has also developed a measurement tool to accurately document the severity of bleeding episodes. She is a recipient of several operating grants from Canadian Blood Services and a McMaster Department of Medicine Internal Career Award.

Clinical Focus

Dr. Webert's clinical interests include transfusion medicine, benign hematology, and hemostasis and coagulation. 

Academic Interests

Academic Interests

Dr. Kathryn Webert is an Associate Professor with the Department of Medicine and the Department of Molecular Medicine and Pathology, and an investigator with the McMaster Transfusion Research Program. She is the Medical Director of Utilization for Canadian Blood Services.  Dr. Webert is involved in teaching medical residents within the Hematology, Internal Medicine, Pathology and Transfusion Medicine residency programs.


Selected Publications

  • Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AA. Platelet Transfusion: A Clinical Practice Guideline From the AABB. Ann Intern Med. 2015; 162:205-213.
  • Traore AN, Chan AK, Webert KE, Heddle N, Ritchie B, St-Louis J, Teitel J, Lillicrap D, Iorio A, Walker I. First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. Haemophilia. 2014 Jul;20:e251-259.
  • Lane SJ, Walker I, Chan AK, Heddle NM, Poon MC, Minuk L, Jardine L, Arnold E, Sholapur N, Webert KE. Treatment decision-making among Canadian youth with severe haemophilia: a qualitative approach. Haemophilia. 2015; 21:180-189.
  • Heddle NM, Lane SJ, Sholapur N, Arnold E, Newbold B, Eyles J, Webert KE. Implementation and public acceptability: lessons from food irradiation and how they might apply to pathogen reduction in blood products. Vox Sang. 2014;107(1):50-9.
  • Arnold E, Lane S, Webert KE, Chan A, Walker I, Tufts J, Rubin S, Poon MC, Heddle NM. What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia. Haemophilia. 2014; 20:219-25.
  • Lane S, Arnold E, Webert KE, Chan A, Walker I, Heddle NM. What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers. Haemophilia. 2013; 19(4):503-10. 
  • Webert KE.  Acquired hemophilia A.  Semin Thromb Hemost 2012; 38:735-741.
  • Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM.  A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia.  Transfusion 2012; 52:2466-2474.
  • Heddle NM, Cook RJ, Arnold DM, Crowther MA, Warkentin TE, Webert KE, Hirsh J, Barty RL, Liu Y, Lester C, Eikelboom JW.  The effect of blood storage duration on in-hospital mortality:  a randomized controlled pilot feasibility trial.  Transfusion 2012; 52: 1203-1212.
  • Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, Saint-Louis J, Walker I.  Low prevalence of inhibitor antibodies in the Canadian haemophilia population.  Haemophilia 2012; 18:e254-259.
  • Eyles J, Heddle N, Webert K, Arnold E, McCurdy B.  Do expert assessments converge?  An exploratory case study of evaluating and managing a blood supply risk.  BMC Public Health 2011; 11:666.
  • Heddle NM, Lui Y, Barty R, Webert KE, Whittaker S, Gagliardi KF, Lauzon D, Owens W.  Factors affecting the frequency of red cell outdates:  an approach to establishing benchmarking targets.  Transfusion 2009; 49:219-226.
  • Heddle NM, Eyles J, Webert KE, Arnold E, McCurdy BR. A policy informing qualitative study to improve the process of blood product recalls and withdrawals. Transfusion 2008; 48:2585-2595.
  • Carcao MD, Webert KE. On-label versus off-label use of recombinant activated factor VII: a comprehensive review of use in two Canadian centers. Semin Hematol. 2008;45(2 Suppl 1):S68-71.
  • Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA, Lipton JH, Brandwein JM, Heddle NM. A multicenter pilot randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008; 48(1): 81-91.

Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0